Abstract
Background: Limited information is available about long-term pamidronate treatment in adults with fibrous dysplasia (FD) of bone.
Objective: The aim of this case series was to report the clinical outcomes and the biochemical and densitometric findings in a group of young adult patients with polyostotic FD treated for ≥3 years with IV pamidronate.
Methods: Pamidronate was administered every 6 months (60 mg/d for 3 days) for 2 years. Thereafter, treatment was individualized. Pamidronate was administered at shorter or longer intervals based on response. Bone pain, radiography, serum bone alkaline phosphatase (BALP) activity, and urinary C-terminal cross-linking telopep-tide of type I collagen (CTX-I) concentration were assessed for a mean of 7 years. Bone mineral density (BMD) of FD areas (FDas) and contralateral areas (CLas) were measured at baseline and at 12 and 24 months. Data were collected prospectively.
Results: Seven patients (5 women, 2 men; mean [SD] age, 31.0 [7.2] years [range, 22–43 years]) were included in the study. Patients received IV pamidronate for a mean of 6.9 years (median, 7.1 years [range, 3.7–10.9 years]). Pamidronate was associated with a reduction in bone pain and a significant reduction in BALP in all patients at the end of follow-up (P < 0.02). The mean reduction from baseline in CTX-I concentration (measured in 3 patients) was 56%; this difference was not significant. Mean BMD values of FDas were significantly increased at 12 months (by 5.9%; P < 0.05) compared with baseline; but was not significantly increased at 24 months (7.3%), probably reflecting a higher dispersion of values due to individual responses to treatment. No significant changes were observed in CLa BMDs. Mean BMD of FDa had a numerically lower decrease of 15.3% compared with CLa at baseline; these decreases with pamidronate were 10.8% at 12 months (P = NS) and 9.3% at 24 months (P < 0.05). Refilling of osteolytic lesions was not observed.
Conclusions: These patients with FD of bone treated with IV pamidronate long term had improvement in bone pain and BMD. The effectiveness of individualized pamidronate administration in the long-term treatment of FD in adult patients should be investigated in blinded controlled trials.
Key words: pamidronate, fibrous dysplasia, bone mineral density, bone pain, bone markers, bone alkaline phosphatase
Full Text
The Full Text of this article is available as a PDF (117.0 KB).
References
- 1.Liens D, Delmas PD, Meunier PJ. Long-term effects of intravenous Pamidronate in fibrous dysplasia of bone. Lancet. 1994;343:953–954. doi: 10.1016/s0140-6736(94)90069-8. [DOI] [PubMed] [Google Scholar]
- 2.Chapurlat RD, Delmas PD, Liens D, Meunier PJ. Long-term effects of intravenous Pamidronate in fibrous dysplasia of bone. J Bone Miner Res. 1997;12:1746–1752. doi: 10.1359/jbmr.1997.12.10.1746. [DOI] [PubMed] [Google Scholar]
- 3.Weinstein RS. Long-term aminobisphosphonate treatment of fibrous dysplasia: Spectacular increase in bone density. J Bone Miner Res. 1997;12:1314–1315. doi: 10.1359/jbmr.1997.12.8.1314. [DOI] [PubMed] [Google Scholar]
- 4.Pfeilschifter J, Ziegler R. Effect of Pamidronate on clinical symptoms and bone metabolism in fibrous dysplasia and McCune-Albright syndrome [in German] Med Klin (Munich) 1998;93:352–359. doi: 10.1007/BF03044679. [DOI] [PubMed] [Google Scholar]
- 5.Lane JM, Khan SN, O’Connor WJ. Bisphosphonate therapy in fibrous dysplasia. Clin Ortbop Relat Res. 2001;382:6–12. doi: 10.1097/00003086-200101000-00003. [DOI] [PubMed] [Google Scholar]
- 6.Parisi MS, Oliveri MB, Mautalen CA. Bone mineral density response to long-term bisphos-phonate therapy in fibrous dysplasia. J Clin Densitom. 2001;4:167–172. doi: 10.1385/jcd:4:2:167. [DOI] [PubMed] [Google Scholar]
- 7.Parisi MS, Oliveri B, Mautalen CA. Effect of intravenous Pamidronate on bone markers and local bone mineral density in fibrous dysplasia. Bone. 2003;33:582–588. doi: 10.1016/s8756-3282(03)00221-7. [DOI] [PubMed] [Google Scholar]
- 8.Chapurlat RD, Hugueny P, Delmas PD, Meunier PJ. Treatment of fibrous dysplasia of bone with intravenous Pamidronate: Long-term effectiveness and evaluation of predictors of response to treatment. Bone. 2004;35:235–242. doi: 10.1016/j.bone.2004.03.004. [DOI] [PubMed] [Google Scholar]
- 9.Chapurlat RD. Medical therapy in adults with fibrous dysplasia of bone. J Bone Miner Res. 2006;21(Suppl 2):P114–P119. doi: 10.1359/jbmr.06s222. [DOI] [PubMed] [Google Scholar]
- 10.Lala R, Matarazzo P, Bertelloni S. Pamidronate treatment of bone fibrous dysplasia in nine children with McCune-Albright syndrome. Acta Paediatr. 2000;89:188–193. doi: 10.1080/080352500750028816. [DOI] [PubMed] [Google Scholar]
- 11.Zacharin M, O’Sullivan M. Intravenous Pamidronate of polyostotic fibrous dysplasia associated with the McCune Albright syndrome. J Pediatr. 2000;137:403–409. doi: 10.1067/mpd.2000.107836. [DOI] [PubMed] [Google Scholar]
- 12.Isaia GC, Lala R, Defilippi C. Bone turnover in children and adolescents with McCune-Albright syndrome treated with Pamidronate for bone fibrous dysplasia. Calcif Tissue Int. 2002;71:121–128. doi: 10.1007/s00223-001-1098-7. [DOI] [PubMed] [Google Scholar]
- 13.O’Sullivan M, Zacharin M. Intramedullary rodding and bisphosphonate treatment of polyostotic fibrous dysplasia associated with the McCune-Albright syndrome. J Pediatr Ortbop. 2002;22:255–260. [PubMed] [Google Scholar]
- 14.Kos M, Luczak K, Godzinski J, Klempous J. Treatment of monostotic fibrous dysplasia with Pamidronate. J Craniomaxillofac Surg. 2004;32:10–15. doi: 10.1016/j.jcms.2003.07.009. [DOI] [PubMed] [Google Scholar]
- 15.Plotkin H, Rauch F, Zeitlin L. Effect of Pamidronate treatment in children with polyostotic fibrous dysplasia of bone. J Clin Endocrinol Metab. 2003;88:4569–4575. doi: 10.1210/jc.2003-030050. [DOI] [PubMed] [Google Scholar]
- 16.Chan B, Zacharin M. Pamidronate treatment of polyostotic fibrous dysplasia: Failure to prevent expansion of dysplastic lesions during childhood. J Pediatr Endocrinol Metab. 2006;19:75–80. doi: 10.1515/jpem.2006.19.1.75. [DOI] [PubMed] [Google Scholar]
- 17.Lala R, Matarazzo P, Andreo M, the Study Group for Gs alpha Protein Related Diseases of the Italian Society for Pediatric Endocrinology and Diabetes Bisphosphonate treatment of bone fibrous dysplasia in McCune-Albright syndrome. J Pediatr Endocrinol Metab. 2006;19(Suppl 2):583–593. doi: 10.1515/jpem.2006.19.s2.583. [DOI] [PubMed] [Google Scholar]
- 18.Chapurlat R, Meunier PJ. Bisphosponates and bone remodeling: Effectiveness in Paget's disease, fibrous dysplasia and osteoporosis [in French] Rev Chir Ortbop Reparatrice Appar Mot. 1998;84:743–751. [PubMed] [Google Scholar]
- 19.Farley JR, Hall SL, Ilacas D. Quantification of skeletal alkaline phosphatase in osteoporotic serum by wheat germ agglutinin precipitation, heat inactivation, and a two-site immuno-radiometric assay. Clin Chem. 1994;40:1749–1756. [PubMed] [Google Scholar]
- 20.Collins MT, Chebli C, Jones J. Renal phosphate wasting in fibrous dysplasia of bone is part of a generalized renal tubular dysfunction similar to that seen in tumor-induced osteomalacia. J Bone Miner Res. 2001;16:806–813. doi: 10.1359/jbmr.2001.16.5.806. [DOI] [PubMed] [Google Scholar]
- 21.Dauty M, Perrouin Verbe B, Maugars Y. Supralesional and sublesional bone mineral density in spinal cord-injured patients. Bone. 2000;27:305–309. doi: 10.1016/s8756-3282(00)00326-4. [DOI] [PubMed] [Google Scholar]
- 22.Pettersson U, Stålnacke BM, Ahlénius G. Low bone mass density at multiple skeletal sites, including the appendicular skeleton in amenorrheic runners. Calcif Tissue Int. 1999;64:117–125. doi: 10.1007/s002239900589. [DOI] [PubMed] [Google Scholar]
- 23.Pettersson U, Alfredson H, Nordström P. Bone mass in female cross-country skiers: Relationship between muscle strength and different BMD sites. Calcif Tissue Inf. 2000;67:199–206. doi: 10.1007/s002230001117. [DOI] [PubMed] [Google Scholar]
- 24.Joshua F, Epstein M, Major G. Biphosphonate resistance in Paget's disease of bone. Arthritis Rheum. 2003;48:2321–2323. doi: 10.1002/art.11136. [DOI] [PubMed] [Google Scholar]
- 25.Hart ES, Kelly MH, Brillante B. Onset, progression, and plateau of skeletal lesions in fibrous dysplasia and the relationship to functional outcome. J Bone Miner Res. 2007;22:1468–1474. doi: 10.1359/jbmr.070511. [DOI] [PubMed] [Google Scholar]